GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...
Abbisko announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically si...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...
a clinical-stage biotechnology company developing novel immunotherapies, announced the company will deliver poster presentations at the Society for I...
IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66th Am...
Agilent Technologies Inc. (NYSE: A) announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and&n...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...
bluebird bio, Inc. (Nasdaq: BLUE) announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...
At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highligh...
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic c...
GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the initiation of INTerpath-009, a piv...
Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...
© 2025 Biopharma Boardroom. All Rights Reserved.
